GILD
Income statement / Annual
Last year (2023), Gilead Sciences, Inc.'s total revenue was $27.12 B,
a decrease of 0.60% from the previous year.
In 2023, Gilead Sciences, Inc.'s net income was $5.67 B.
See Gilead Sciences, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$27.12 B
|
$27.28 B
|
$27.31 B
|
$24.69 B
|
$22.45 B
|
$22.13 B
|
$26.11 B
|
$30.39 B
|
$32.64 B
|
$24.89 B
|
| Cost of Revenue |
$5.97 B |
$5.66 B |
$6.60 B |
$4.57 B |
$4.68 B |
$4.85 B |
$4.37 B |
$4.26 B |
$4.01 B |
$3.79 B |
| Gross Profit |
$21.15 B |
$21.62 B |
$20.70 B |
$20.12 B |
$17.77 B |
$17.27 B |
$21.74 B |
$26.13 B |
$28.63 B |
$21.10 B |
| Gross Profit Ratio |
0.78 |
0.79 |
0.76 |
0.81 |
0.79 |
0.78 |
0.83 |
0.86 |
0.88 |
0.85 |
| Research and Development
Expenses |
$5.72 B
|
$4.98 B
|
$5.36 B
|
$5.04 B
|
$9.11 B
|
$5.02 B
|
$3.73 B
|
$5.10 B
|
$3.01 B
|
$2.85 B
|
| General & Administrative
Expenses |
$5.23 B
|
$4.90 B
|
$4.51 B
|
$4.36 B
|
$3.60 B
|
$4.06 B
|
$3.88 B
|
$3.40 B
|
$3.43 B
|
$2.98 B
|
| Selling & Marketing
Expenses |
$826.00 M
|
$778.00 M
|
$735.00 M
|
$795.00 M
|
$784.00 M
|
$587.00 M
|
$600.00 M
|
$618.00 M
|
$601.00 M
|
$393.00 M
|
| Selling, General &
Administrative Expenses |
$6.06 B
|
$5.67 B
|
$5.25 B
|
$5.15 B
|
$4.38 B
|
$4.06 B
|
$3.88 B
|
$3.40 B
|
$3.43 B
|
$2.98 B
|
| Other Expenses |
$198.00 M |
-$581.00 M |
-$639.00 M |
-$1.42 B |
$1.87 B |
$676.00 M |
$523.00 M |
$428.00 M |
$154.00 M |
$3.00 M |
| Operating Expenses |
$11.78 B |
$10.65 B |
$10.61 B |
$10.19 B |
$13.49 B |
$9.07 B |
$7.61 B |
$8.50 B |
$6.44 B |
$5.84 B |
| Cost And Expenses |
$17.75 B |
$16.31 B |
$17.21 B |
$14.76 B |
$18.16 B |
$13.93 B |
$11.98 B |
$12.76 B |
$10.45 B |
$9.63 B |
| Interest Income |
$376.00 M |
$935.00 M |
$1.00 B |
$984.00 M |
$995.00 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$944.00 M |
$935.00 M |
$1.00 B |
$984.00 M |
$995.00 M |
$1.08 B |
$1.12 B |
$964.00 M |
$688.00 M |
$412.00 M |
| Depreciation &
Amortization |
$2.69 B
|
$2.10 B
|
$2.05 B
|
$1.48 B
|
$1.40 B
|
$1.43 B
|
$1.29 B
|
$1.16 B
|
$1.10 B
|
$1.05 B
|
| EBITDA |
$11.70 B
|
$10.39 B
|
$9.46 B
|
$8.51 B
|
$6.16 B
|
$8.88 B
|
$14.65 B
|
$18.06 B
|
$22.35 B
|
$15.27 B
|
| EBITDA Ratio |
0.43 |
0.38 |
0.35 |
0.34 |
0.27 |
0.4 |
0.56 |
0.59 |
0.68 |
0.61 |
| Operating Income Ratio
|
0.35
|
0.27
|
0.27
|
0.28
|
0.19
|
0.37
|
0.54
|
0.58
|
0.68
|
0.61
|
| Total Other
Income/Expenses Net |
-$2.51 B
|
-$1.52 B
|
$872.00 M
|
-$5.36 B
|
$873.00 M
|
$676.00 M
|
$523.00 M
|
$428.00 M
|
$154.00 M
|
$3.00 M
|
| Income Before Tax |
$6.86 B |
$5.81 B |
$8.28 B |
$1.67 B |
$5.16 B |
$7.80 B |
$13.53 B |
$17.10 B |
$21.66 B |
$14.86 B |
| Income Before Tax Ratio
|
0.25
|
0.21
|
0.3
|
0.07
|
0.23
|
0.35
|
0.52
|
0.56
|
0.66
|
0.6
|
| Income Tax Expense |
$1.25 B |
$1.25 B |
$2.08 B |
$1.58 B |
-$204.00 M |
$2.34 B |
$8.89 B |
$3.61 B |
$3.55 B |
$2.80 B |
| Net Income |
$5.67 B |
$4.59 B |
$6.23 B |
$89.00 M |
$5.39 B |
$5.46 B |
$4.63 B |
$13.50 B |
$18.11 B |
$12.10 B |
| Net Income Ratio |
0.21 |
0.17 |
0.23 |
0 |
0.24 |
0.25 |
0.18 |
0.44 |
0.55 |
0.49 |
| EPS |
4.54 |
3.66 |
4.96 |
0.0708 |
4.24 |
4.2 |
3.54 |
10.08 |
12.37 |
7.95 |
| EPS Diluted |
4.5 |
3.64 |
4.93 |
0.0705 |
4.22 |
4.17 |
3.51 |
9.94 |
11.91 |
7.35 |
| Weighted Average Shares
Out |
$1.25 B
|
$1.26 B
|
$1.26 B
|
$1.26 B
|
$1.27 B
|
$1.30 B
|
$1.31 B
|
$1.34 B
|
$1.46 B
|
$1.52 B
|
| Weighted Average Shares
Out Diluted |
$1.26 B
|
$1.26 B
|
$1.26 B
|
$1.26 B
|
$1.28 B
|
$1.31 B
|
$1.32 B
|
$1.36 B
|
$1.52 B
|
$1.65 B
|
| Link |
|
|
|
|
|
|
|
|
|
|
